{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:37:20Z","timestamp":1773023840213,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11916-020-00854-y","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T10:02:22Z","timestamp":1584784942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease"],"prefix":"10.1007","volume":"24","author":[{"given":"Jacob","family":"Fiocchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vwaire","family":"Orhurhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam Salisu","family":"Orhurhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Giacomazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briggs","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"issue":"11","key":"854_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1056\/NEJM199709113371107","volume":"337","author":"HF Bunn","year":"1997","unstructured":"Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762\u20139.","journal-title":"N Engl J Med"},{"issue":"7989","key":"854_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0140-6736(76)90612-7","volume":"2","author":"MT Ashcroft","year":"1976","unstructured":"Ashcroft MT, Desai P. Mortality and morbidity in Jamaican adults with sickle-cell trait and with normal haemoglobin followed up for twelve years. Lancet. 1976;2(7989):784\u20136.","journal-title":"Lancet."},{"issue":"9","key":"854_CR3","first-page":"1300","volume":"77","author":"UPST Force","year":"2008","unstructured":"Force UPST. Screening for sickle cell disease in newborns: recommendation statement. Am Fam Physician. 2008;77(9):1300\u20132.","journal-title":"Am Fam Physician"},{"key":"854_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/B978-0-12-802973-2.00018-5","volume":"138","author":"J Strouse","year":"2016","unstructured":"Strouse J. Chapter 18 - sickle cell disease. Handb Clin Neurol. 2016;138:311\u201324.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"854_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.mcna.2016.09.009","volume":"101","author":"S Azar","year":"2017","unstructured":"Azar S, Wong TE. Sickle cell disease: a brief update. Med Clin North Am. 2017;101(2):375\u201393.","journal-title":"Med Clin North Am"},{"issue":"4","key":"854_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ajhg.2018.02.003","volume":"102","author":"D Shriner","year":"2018","unstructured":"Shriner D, Rotimi CN. Whole-genome-sequence-based haplotypes reveal single origin of the sickle allele during the Holocene wet phase. Am J Hum Genet. 2018;102(4):547\u201356.","journal-title":"Am J Hum Genet"},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT. Sickle cell disease. Lancet. 2010;376:2018\u201331.","journal-title":"Lancet."},{"issue":"1","key":"854_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjhp.12157","volume":"21","author":"B Coleman","year":"2016","unstructured":"Coleman B, Ellis-Caird H, McGowan J, Benjamin MJ. How sickle cell disease patients experience, understand and explain their pain: an interpretative phenomenological analysis study. Br J Health Psychol. 2016;21(1):190\u2013203.","journal-title":"Br J Health Psychol"},{"issue":"1","key":"854_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood.V67.1.46.46","volume":"67","author":"JB Sherwood","year":"1986","unstructured":"Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood. 1986;67(1):46\u20139.","journal-title":"Blood."},{"issue":"8","key":"854_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0895-4356(92)90073-V","volume":"45","author":"MS West","year":"1992","unstructured":"West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol. 1992;45(8):893.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"854_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1182\/blood-2005-09-008318","volume":"108","author":"RS Franco","year":"2006","unstructured":"Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006;108(3):1073\u20136.","journal-title":"Blood."},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4137\/NMI.S5048","volume":"3","author":"HI Hyacinth","year":"2010","unstructured":"Hyacinth HI, Gee BE, Hibbert JM. The role of nutrition in sickle cell disease. Nutr Metab Insights. 2010;3:57.","journal-title":"Nutr Metab Insights"},{"issue":"4","key":"854_CR13","first-page":"275","volume":"28","author":"EN Dessypris","year":"1991","unstructured":"Dessypris EN. The biology of pure red cell aplasia. Semin Hematol. 1991;28(4):275\u201384.","journal-title":"Semin Hematol"},{"issue":"2","key":"854_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0022-3476(85)80125-6","volume":"107","author":"AM Emond","year":"1985","unstructured":"Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107(2):201\u20136.","journal-title":"J Pediatr"},{"issue":"9","key":"854_CR15","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1182\/blood-2010-04-278747","volume":"117","author":"ZR Rogers","year":"2011","unstructured":"Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood. 2011;117(9):2614.","journal-title":"Blood."},{"issue":"11","key":"854_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1086\/516781","volume":"44","author":"NB Halasa","year":"2007","unstructured":"Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428\u201333.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"854_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3476(05)81847-5","volume":"118","author":"JF Marcinak","year":"1991","unstructured":"Marcinak JF, Frank AL, Labotka RL, Rao S, Drawhorn L, Dampief C, et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 3- to 17-month-old infants with sickle cell diseases. J Pediatr. 1991;118(1):69\u201371.","journal-title":"J Pediatr"},{"key":"854_CR18","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2010-05-282194","volume":"116","author":"JJ Strouse","year":"2010","unstructured":"Strouse JJ, Reller ME, Bundy DG, Amoako M, Cancio M, Han RN, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood. 2010;116:3431\u20134.","journal-title":"Blood"},{"issue":"10","key":"854_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. J Am Med Assoc. 2014;312(10):1033\u201348.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"854_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM199807023390102","volume":"339","author":"RJ Adams","year":"1998","unstructured":"Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5\u201311.","journal-title":"N Engl J Med"},{"issue":"3","key":"854_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2141.2010.08344.x","volume":"151","author":"SB Ali","year":"2010","unstructured":"Ali SB, Reid M, Fraser R, MooSang M, Ali A. Seizures in the Jamaica cohort study of sickle cell disease. Br J Haematol. 2010;151(3):265\u201372.","journal-title":"Br J Haematol"},{"issue":"1","key":"854_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/MPH.0000000000001012","volume":"40","author":"GD Patterson","year":"2018","unstructured":"Patterson GD, Mashegu H, Rutherford J, Seals S, Josey D, Karlson C, et al. Recurrent acute chest syndrome in pediatric sickle cell disease: clinical features and risk factors. J Pediatr Hematol Oncol. 2018;40(1):51\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"854_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM199509143331104","volume":"333","author":"P Bellet","year":"1995","unstructured":"Bellet P, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333(11):699.","journal-title":"N Engl J Med"},{"issue":"3","key":"854_CR24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1542\/peds.2010-1791","volume":"128","author":"CJ Wang","year":"2011","unstructured":"Wang CJ, Kavanagh PL, Little AA, Holliman JB, Sprinz PG. Quality-of-care indicators for children with sickle cell disease. Pediatrics. 2011;128(3):484\u201393.","journal-title":"Pediatrics."},{"issue":"2","key":"854_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","volume":"102","author":"CH Pegelow","year":"1997","unstructured":"Pegelow CH, Colangelo L, Steinberg M, Wright EC, Smith J, Phillips G, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102(2):171.","journal-title":"Am J Med"},{"issue":"10037","key":"854_CR26","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","volume":"387","author":"MT Gladwin","year":"2016","unstructured":"Gladwin MT. Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016;387(10037):2565.","journal-title":"Lancet."},{"issue":"1","key":"854_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/asheducation-2017.1.435","volume":"2017","author":"E Vichinsky","year":"2017","unstructured":"Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematology. 2017;2017(1):435\u20139.","journal-title":"Hematology."},{"issue":"1","key":"854_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.1982.tb01887.x","volume":"50","author":"H Hawker","year":"1982","unstructured":"Hawker H, Neilson H, Hayes RJ, Serjeant GR. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol. 1982;50(1):29.","journal-title":"Br J Haematol"},{"issue":"12","key":"854_CR29","doi-asserted-by":"publisher","first-page":"E666","DOI":"10.1002\/ajh.24918","volume":"92","author":"VM Pinto","year":"2017","unstructured":"Pinto VM, Gianesin B, Balocco M, Bacigalupo L, Forni GL. Noninvasive monitoring of liver fibrosis in sickle cell disease: longitudinal observation of a cohort of adult patients. Am J Hematol. 2017;92(12):E666\u20138.","journal-title":"Am J Hematol"},{"issue":"1","key":"854_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM199107043250103","volume":"325","author":"OS Platt","year":"1991","unstructured":"Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11.","journal-title":"N Engl J Med"},{"issue":"1","key":"854_CR31","doi-asserted-by":"publisher","first-page":"421058352","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis. 2019;14(1):421058352.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"22","key":"854_CR32","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","volume":"130","author":"H Tran","year":"2017","unstructured":"Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017;130(22):2377\u201385.","journal-title":"Blood."},{"issue":"5","key":"854_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","volume":"18","author":"C Dampier","year":"2017","unstructured":"Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell disease pain. J Pain. 2017;18(5):490\u20138.","journal-title":"J Pain"},{"issue":"5","key":"854_CR34","doi-asserted-by":"publisher","first-page":"e0178353","DOI":"10.1371\/journal.pone.0178353","volume":"12","author":"P Chalacheva","year":"2017","unstructured":"Chalacheva P, Khaleel M, Sunwoo J, Shah P, Detterich JA, Kato RM, et al. Biophysical markers of the peripheral vasoconstriction response to pain in sickle cell disease. Connes P, editor. PLoS One. 2017;12(5):e0178353.","journal-title":"PLoS One"},{"issue":"1","key":"854_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/asheducation-2017.1.534","volume":"2017","author":"DS Darbari","year":"2017","unstructured":"Darbari DS, Brandow AM. Pain-measurement tools in sickle cell disease: where are we now? Hematol Am Soc Hematol Educ Progr. 2017;2017(1):534\u201341.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"3","key":"854_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.hoc.2018.01.014","volume":"32","author":"AM Brandow","year":"2018","unstructured":"Brandow AM, DeBaun MR. Key components of pain management for children and adults with sickle cell disease. Hematol Oncol Clin North Am. 2018;32(3):535\u201350.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"854_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/ajh.24858","volume":"92","author":"M Khaleel","year":"2017","unstructured":"Khaleel M, Puliyel M, Shah P, Sunwoo J, Kato RM, Chalacheva P, et al. Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain. Am J Hematol. 2017;92(11):1137\u201345.","journal-title":"Am J Hematol"},{"issue":"5","key":"854_CR38","first-page":"152","volume":"168","author":"S Master","year":"2016","unstructured":"Master S, Patel A, Mills G, Mansour R. Objective basis for chronic pain in patients with adult sickle cell disease. J La State Med Soc. 2016;168(5):152\u20135.","journal-title":"J La State Med Soc"},{"issue":"Suppl 1","key":"854_CR39","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/j.pain.0000000000000824","volume":"158","author":"AM Brandow","year":"2017","unstructured":"Brandow AM, Zappia KJ, Stucky CL. Sickle cell disease: a natural model of acute and chronic pain. Pain. 2017;158(Suppl 1):S79\u201384.","journal-title":"Pain"},{"issue":"2","key":"854_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/pr.2017.197","volume":"83","author":"R Nobrega","year":"2018","unstructured":"Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZMN. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. Pediatr Res. 2018;83(2):445\u201354.","journal-title":"Pediatr Res"},{"issue":"1","key":"854_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/15360288.2018.1468383","volume":"32","author":"N Palm","year":"2018","unstructured":"Palm N, Floroff C, Hassig TB, Boylan A, Kanter J. Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. J Pain Palliat Care Pharmacother. 2018;32(1):20\u20136.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"854_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","volume":"18","author":"FA Lubega","year":"2018","unstructured":"Lubega FA, DeSilva MS, Munube D, Nkwine R, Tumukunde J, Agaba PK, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018;18(1):19\u201327.","journal-title":"Scand J Pain"},{"issue":"7","key":"854_CR43","doi-asserted-by":"publisher","first-page":"e017190","DOI":"10.1136\/bmjopen-2017-017190","volume":"7","author":"JR Young","year":"2017","unstructured":"Young JR, Sawe HR, Mfinanga JA, Nshom E, Helm E, Moore CG, et al. Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial. BMJ Open. 2017;7(7):e017190.","journal-title":"BMJ Open"},{"key":"854_CR44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.ajem.2017.11.015","volume":"36","author":"GS Kelly","year":"2018","unstructured":"Kelly GS, Stewart RW, Strouse JJ, Anders JF. Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. Am J Emerg Med. 2018;36:1305\u20137.","journal-title":"Am J Emerg Med"},{"key":"854_CR45","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ajem.2017.10.060","volume":"36","author":"J Vaux","year":"2018","unstructured":"Vaux J, Thierry M, Cunha D, Marty J. Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. Am J Emerg Med. 2018;36:1300\u201320.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"854_CR46","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/papr.12674","volume":"18","author":"V Rousseau","year":"2018","unstructured":"Rousseau V, Morelle M, Arriuberge C, Darnis S, Chabaud S, Launay V, et al. Efficacy and tolerance of Lidocaine 5% patches in neuropathic pain and pain related to vaso-occlusive sickle cell crises in children: a prospective multicenter clinical study. Pain Pract. 2018;18(6):788\u201397.","journal-title":"Pain Pract"},{"key":"854_CR47","doi-asserted-by":"publisher","first-page":"E99","DOI":"10.1002\/ajh.25032","volume":"93","author":"JE Brittain","year":"2018","unstructured":"Brittain JE, Anea C, Desai P, Delaney J, McDonald A, Looney SW, et al. Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. Am J Hematol. 2018;93:E99\u2013101.","journal-title":"Am J Hematol"},{"issue":"18","key":"854_CR48","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/bloodadvances.2018018382","volume":"2","author":"S Lanzkron","year":"2018","unstructured":"Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, et al. Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv. 2018;2(18):2412\u20137.","journal-title":"Blood Adv"},{"key":"854_CR49","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0009922816674521","volume":"56","author":"C Cacciotti","year":"2017","unstructured":"Cacciotti C, Vaiselbuh S, Romanos-Sirakis E. Pain management for sickle cell disease in the pediatric emergency department: medications and hospitalization trends. Clin Pediatr. 2017;56:1109\u201314.","journal-title":"Clin Pediatr"},{"issue":"3","key":"854_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5055\/jom.2015.0273","volume":"11","author":"WR Smith","year":"2015","unstructured":"Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, Citero V, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project. J Opioid Manag. 2015;11(3):243\u201353.","journal-title":"J Opioid Manag"},{"issue":"1","key":"854_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/PEC.0000000000000978","volume":"35","author":"JM Hagedorn","year":"2019","unstructured":"Hagedorn JM, Monico EC. Ketamine infusion for pain control in acute pediatric sickle cell painful crises. Pediatr Emerg Care. 2019;35(1):78\u20139.","journal-title":"Pediatr Emerg Care"},{"issue":"20","key":"854_CR52","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","volume":"1","author":"JJ Field","year":"2017","unstructured":"Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 2017;1(20):1645\u20139.","journal-title":"Blood Adv"},{"issue":"7","key":"854_CR53","first-page":"417","volume":"43","author":"TR Riley","year":"2018","unstructured":"Riley TR, Boss A, McClain D, Riley TT. Review of medication therapy for the prevention of sickle cell crisis. PT. 2018;43(7):417\u201337.","journal-title":"PT"},{"issue":"5","key":"854_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pds.4291","volume":"27","author":"J Han","year":"2018","unstructured":"Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018;27(5):479\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1 Suppl 1","key":"854_CR55","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","volume":"51","author":"CP Carroll","year":"2016","unstructured":"Carroll CP, Lanzkron S, Haywood C, Kiley K, Pejsa M, Moscou-Jackson G, et al. Chronic opioid therapy and central sensitization in sickle cell disease. Am J Prev Med. 2016;51(1 Suppl 1):S69\u201377.","journal-title":"Am J Prev Med"},{"issue":"5","key":"854_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11916-019-0773-1","volume":"23","author":"I Urits","year":"2019","unstructured":"Urits I, Viswanath O, Orhurhu V, Gress K, Charipova K, Kaye AD, et al. The utilization of mu-opioid receptor biased agonists: oliceridine, an opioid analgesic with reduced adverse effects. Curr Pain Headache Rep. 2019;23(5):31.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"854_CR57","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/asheducation-2017.1.406","volume":"2017","author":"JJ Field","year":"2017","unstructured":"\u2022 Field JJ. Five lessons learned about long-term pain management in adults with sickle cell disease. Hematol Am Soc Hematol Educ Progr. 2017;2017(1):406\u201311. A systematic review of vasoocclussive crisis prevention in sickle cell disease.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"19","key":"854_CR58","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/bloodadvances.2017007211","volume":"1","author":"JWR Sins","year":"2017","unstructured":"Sins JWR, Mager DJ, Davis SCAT, Biemond BJ, Fijnvandraat K. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Adv. 2017;1(19):1598\u2013616.","journal-title":"Blood Adv"},{"issue":"5","key":"854_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"854_CR60","first-page":"798","volume":"317","author":"A Slomski","year":"2017","unstructured":"Slomski A. Crizanlizumab prevents sickle cell pain crises. JAMA. 2017;317(8):798.","journal-title":"JAMA."},{"issue":"4","key":"854_CR61","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/bjh.14580","volume":"177","author":"C Hoppe","year":"2017","unstructured":"Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017;177(4):620\u20139.","journal-title":"Br J Haematol"},{"issue":"12","key":"854_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27420","volume":"65","author":"J Payne","year":"2018","unstructured":"Payne J, Aban I, Hilliard LM, Madison J, Bemrich-Stolz C, Howard TH, et al. Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis. Pediatr Blood Cancer. 2018;65(12):e27420.","journal-title":"Pediatr Blood Cancer"},{"key":"854_CR63","first-page":"CD012082","volume":"2018","author":"PM Fortin","year":"2018","unstructured":"Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018;2018:CD012082.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"854_CR64","first-page":"4652","volume":"130","author":"DD Park","year":"2017","unstructured":"Park DD, Jacob DG, Adedemola A, Mowatt K, Persaud T, Tipirneni A, et al. Sickle cell disease and the adherence to guidelines for use of blood transfusions. Blood. 2017;130(Suppl 1):4652.","journal-title":"Blood"},{"issue":"4","key":"854_CR65","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.15169","volume":"184","author":"DS Darbari","year":"2018","unstructured":"Darbari DS, Liljencrantz J, Ikechi A, Martin S, Roderick MC, Fitzhugh CD, et al. Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant. Br J Haematol. 2018;184(4):690\u20133.","journal-title":"Br J Haematol"},{"issue":"2","key":"854_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.13123","volume":"168","author":"RM Fasano","year":"2015","unstructured":"Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291\u2013300.","journal-title":"Br J Haematol"},{"key":"854_CR67","doi-asserted-by":"crossref","unstructured":"Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, Dalle JH, Di Bartolomeo P, de Heredia CD, Dickerhoff R, Giardini C, Gluckman E, Hussein AA, Kamani N, Minkov M, Locatelli F, Rocha V, \u2026 Peters C. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811\u2013820.","DOI":"10.3324\/haematol.2013.099747"},{"key":"854_CR68","doi-asserted-by":"crossref","unstructured":"Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, Sim\u00f5es BP, Ferster A, Dupont S, De La Fuente J, Dalle JH, Zecca M, Walters MC, Krishnamurti L, Bhatia M, Leung K, Yanik G, \u2026 Chaudhury S. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548\u20131556.","DOI":"10.1182\/blood-2016-10-745711"},{"key":"854_CR69","doi-asserted-by":"crossref","unstructured":"Shenoy S, Angelucci E, Arnold SD, Baker KS, Bhatia M, Bresters D, Dietz AC, De La Fuente J, Duncan C, Gaziev J, King AA, Pulsipher MA, Smith AR, Walters MC. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium Inte. In: Biology of Blood and Marrow Transplantation. Elsevier; 2017. p. 552\u2013561.","DOI":"10.1016\/j.bbmt.2017.01.009"},{"key":"854_CR70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","volume":"22","author":"MC Walters","year":"2016","unstructured":"Walters MC, De Castro LM, Sullivan KM, Krishnamurti L, Kamani N, Bredeson C, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transpl. Elsevier. 2016;22:207\u201311.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"854_CR71","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","volume":"125","author":"MD Hoban","year":"2015","unstructured":"Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, et al. Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells. Blood. 2015;125(17):2597\u2013604.","journal-title":"Blood."},{"key":"854_CR72","doi-asserted-by":"crossref","unstructured":"Cavazzana M, Ribeil J-A, Payen E, Touzot F, Neven B, Lefrere F, Suarez F, Magrin E, Beuzard Y, Chretien S, Bourget P, Monpoux F, Pondarr\u00e9 C, Bartolucci P, Schmidt M, Leboulch P. Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and \u03b2-thalassemia. In: ASGCT 19th Annual Meeting, Gene Therapy for Non-malignant Diseases. Elsevier; 2016. p. S111.","DOI":"10.1016\/S1525-0016(16)33088-X"},{"issue":"22","key":"854_CR73","doi-asserted-by":"publisher","first-page":"1176 LP","DOI":"10.1182\/blood.V128.22.1176.1176","volume":"128","author":"J Kanter","year":"2016","unstructured":"Kanter J, Walters MC, Hsieh MM, Krishnamurti L, Kwiatkowski J, Kamble RT, et al. Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood. 2016;128(22):1176 LP.","journal-title":"Blood"},{"key":"854_CR74","doi-asserted-by":"crossref","unstructured":"Ribeil J-A, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet J-F, Grevent D, Beuzard Y, Chr\u00e9tien S, \u2026 Cavazzana M. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017;376(9):848\u2013855.","DOI":"10.1056\/NEJMoa1609677"},{"key":"854_CR75","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2147\/JPR.S131859","volume":"10","author":"RR Bhatt","year":"2017","unstructured":"\u2022 Bhatt RR, Martin SR, Evans S, Lung K, Coates TD, Zeltzer LK, et al. The effect of hypnosis on pain and peripheral blood flow in sickle-cell disease: a pilot study. J Pain Res. 2017;10:1635\u201344. Psychotherapy for chronic symptom management in sickle cell disease.","journal-title":"J Pain Res"},{"key":"854_CR76","doi-asserted-by":"publisher","first-page":"e27525","DOI":"10.1002\/pbc.27525","volume":"66","author":"AK Agrawal","year":"2018","unstructured":"Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, et al. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2018;66:e27525.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"854_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MPH.0000000000001018","volume":"40","author":"TM Palermo","year":"2018","unstructured":"Palermo TM, Dudeney J, Santanelli JP, Carletti A, Zempsky WT. Feasibility and acceptability of internet-delivered cognitive behavioral therapy for chronic pain in adolescents with sickle cell disease and their parents. J Pediatr Hematol Oncol. 2018;40(2):122\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"key":"854_CR78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cct.2018.10.006","volume":"74","author":"TM Palermo","year":"2018","unstructured":"Palermo TM, Zempsky WT, Dampier CD, Lalloo C, Hundert AS, Murphy LK, et al. iCanCope with sickle cell pain: design of a randomized controlled trial of a smartphone and web-based pain self-management program for youth with sickle cell disease. Contemp Clin Trials. 2018;74:88\u201396.","journal-title":"Contemp Clin Trials"},{"key":"854_CR79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jpainsymman.2015.10.017","volume":"51","author":"H Williams","year":"2016","unstructured":"Williams H, Tanabe P. Sickle cell disease: a review of nonpharmacological approaches for pain. J Pain Symptom Manag. 2016;51:163\u201377.","journal-title":"J Pain Symptom Manag"},{"key":"854_CR80","first-page":"CD003968","volume":"2018","author":"E Fisher","year":"2018","unstructured":"Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;2018:CD003968.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"854_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.12968\/ijpn.2018.24.5.246","volume":"24","author":"SM Simo","year":"2018","unstructured":"Simo SM, Siela D. Use of a depression and sleep impairment treatment guideline to improve quality of life for patients with sickle cell disease. Int J Palliat Nurs. 2018;24(5):246\u201355.","journal-title":"Int J Palliat Nurs"},{"issue":"5","key":"854_CR82","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/0091217416680839","volume":"51","author":"SO Raji","year":"2016","unstructured":"Raji SO, Lawani AO, James BO. Prevalence and correlates of major depression among Nigerian adults with sickle cell disease. Int J Psychiatry Med. 2016;51(5):456\u201366.","journal-title":"Int J Psychiatry Med"},{"issue":"3-4","key":"854_CR83","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/0886260517691521","volume":"35","author":"JD Ford","year":"2017","unstructured":"Ford JD, Grasso DJ, Jones S, Works T, Andemariam B. Interpersonal violence exposure and chronic pain in adult sickle cell patients. J Interpers Violence. 2017;35(3-4):924\u201342 088626051769152.","journal-title":"J Interpers Violence"},{"issue":"1","key":"854_CR84","first-page":"39","volume":"56","author":"R Sohier","year":"1978","unstructured":"Sohier R, Gaudin OG. Le r\u00f4le du laboratoire de virologie dans un pays en d\u00e9veloppement. Bull World Health Organ. 1978;56(1):39\u201351.","journal-title":"Bull World Health Organ"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-020-00854-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T12:02:14Z","timestamp":1666180934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-020-00854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s11916-020-00854-y","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"21 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jacob Fiocchi, Ivan Urits, Vwaire Orhurhu, Mariam Salisu Orhurhu, Stephen Giacomazzi, Briggs Hoyt, Rachel Kaye and Omar Viswanath declare no conflict of interest.Alan Kaye is a Section Editor for <i>Current Headache and Pain Reports<\/i>. He has not been involved in the editorial handling of this manuscript. Dr. Kaye is also a speaker for Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"17"}}